AI is revolutionizing the life sciences sector, from drug discovery to precision medicine. Its ability to analyze massive datasets and identify potential drug candidates drastically cuts development time and costs. Global giants like Pfizer, Sanofi, and Merck are using Gen AI for drug discovery, while Janssen and Merck leverage it for drug design. Gen AI also assists in data analysis, predicting side effects, and repurposing drugs. In clinical trials, it helps predict roadblocks and improve efficiency. In India, Gen AI is being used for patient-centric applications and drug development, with biotech startups leading the way. While initial adoption was cautious, numerous Gen AI applications are now contributing to highly targeted therapies, putting India on the global clinical trial map. Companies are now creating AI co-pilots to improve efficiency and productivity across the value chain. The focus should be on building a skilled workforce to adapt to these new ways of working.

While the "primum non nocere" principle has historically held back technology adoption in healthcare, the pandemic pushed it forward. In India, while foundational systems like HIS and EMR are widespread, AI adoption remains in its early stages. This delay stems from fragmented data and a shortage of skilled professionals. Gen AI offers a solution, augmenting the healthcare system's capabilities. It can simplify patient journeys, improve clinical documentation, and personalize care plans. However, concerns around job displacement, data privacy, and result accuracy necessitate a cautious approach. Healthcare leaders are exploring pilot programs and building trust before real-world implementation. Gen AI's potential to revolutionize Indian healthcare is undeniable, but success hinges on responsible and ethical adoption.